NXTC
$5.68
Nextcure
$.20
3.65%
NXTC
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.67)
Revenue:  $0.00 Mil
Thursday
Feb 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NXTC reports earnings?
Beat
Meet
Miss

Where is NXTC's stock price going from here?
Up
Flat
Down
Stock chart of NXTC
Analysts
Summary of analysts' recommendations for NXTC
Score
Grade
Pivots
Resistance
$6.06
$5.89
$5.78

$5.61

Support
$5.50
$5.33
$5.22
Tweet
Growth
Description
NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland.